Top Markets
#1 MON MON +2,757.44%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +46.60%
#4 eCash eCash +31.94%
#5 Siren Siren +23.75%
#6 SAFEcoin SAFEcoin +19.98%
#7 Janction Janction +18.96%
#8 PinGo PinGo +15.95%
#9 Velvet Velvet +15.57%
#10 Beldex Beldex +13.32%
Coin of the day
MON MON
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Rang in aandelen #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Aandeelprijs
$0.30780727
Marktkapitalisatie
$94.19M
Verandering (1 dag)
-0.19%
Verandering (1 jaar)
-34.73%
Land
FR
Handel Sensorion SA (ALSEN)

Categorie

Healthcare
Omzet van Sensorion SA (ALSEN)
Omzet in Dec 2025 TTM: $2.73M
Volgens de laatste financiële rapporten van Sensorion SA bedraagt de huidige omzet van het bedrijf (TTM) $2.73M. In 2023 behaalde het bedrijf een omzet van $6.30M een stijging ten opzichte van de omzet in het jaar 2022, die $5.29M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Sensorion SA van 2011 tot 2026
Omzet aan het einde van elk jaar
Jaar Omzet Wijzigen
2026 (TTM) $2.73M -60.56%
2024 $6.92M 9.91%
2023 $6.30M 19.02%
2022 $5.29M 9.15%
2021 $4.85M 69.26%
2020 $2.86M 3.92%
2019 $2.76M 7.54%
2018 $2.56M 10.42%
2017 $2.32M 12,505.95%
2016 $18.41K -89.23%
2015 $171.03K -38.96%
2014 $280.18K -42.85%
2013 $490.29K 60.42%
2012 $305.63K 1,124,142.32%
2011 $27.19 0.00%
Omzet van vergelijkbare bedrijven of concurrenten
Bedrijf Omzet Omzetverschil Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $52.05B 1,906,201.38%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B 448,772.67%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B 546,366.42%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 332,560.08%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.29B 230,302.17%
NL